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ABSTRACT 
Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and associated with 
considerable morbidity and mortality.  Significant advances have recently occurred in the treatment of 
T2DM, with evidence of several new glucose-lowering medications showing either neutral or beneficial 
cardiovascular effects. However, some of these agents have safety characteristics with strong practical 
implications in HF (i.e. dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor 
agonists (GLP-1 RA), and sodium-glucose contransporter-2 (SGLT-2) inhibitors).  
Regarding safety of DPP-4 inhibitors, saxagliptin, is not recommended in HF because of a greater risk 
of HF hospitalisation. There is no compelling evidence of excess HF risk with the other DPP-4 inhibitors. 
GLP-1 RAs have an overall neutral effect on HF outcomes. However, a signal of harm suggested in 
two small trials of liraglutide in patients with reduced ejection fraction, indicates that their role remains 
to be defined in established HF. SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) have 
shown a consistent reduction in the risk of HF hospitalisation regardless of baseline cardiovascular risk 
or history of HF. Accordingly, SGLT-2 inhibitors could be recommended to prevent HF hospitalisation 
in patients with T2DM and established cardiovascular disease or with multiple risk factors. The recently 
completed trial with dapagliflozin, has shown a significant reduction in cardiovascular mortality and HF 
events in patients with HF and reduced ejection fraction, with or without T2DM. Several ongoing trials 
will assess whether the results observed with dapagliflozin could be extended to other SGLT-2 inhibitors 
in the treatment of HF, with either preserved or reduced ejection fraction, regardless of the presence of 
T2DM. This position paper aims to summarise relevant clinical trial evidence concerning the role and 
safety of new glucose-lowering therapies in patients with HF.  
 
 
Key words: heart failure, type 2 diabetes mellitus, cardiovascular risk, hospitalisation, sodium 
glucose cotransporter 2 inhibitor, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 
inhibitor, clinical trial 
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is common (∼20-40%) in patients with heart failure (HF) [1], 
and is associated with worse symptoms and quality of life, a greater burden of HF hospitalization, and 
higher mortality rates compared to patients without T2DM [2-7]. Increased levels of glycosylated 
haemoglobin A1c (HbA1c) have been associated with increased morbidity and mortality in patients with 
T2DM and HF not receiving treatment with glucose-lowering drugs [8, 9]. However, once treatment of 
T2DM has been initiated, this relationship may no longer be linear. Most data suggests that mortality 
risk in patients with HF is lowest with moderate glycaemic control (i.e. HbA1c levels 7.0-7.9%) [10-14]. 
Therefore, the 2016 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment 
of HF stipulate that adequate glycaemic control should be achieved gradually and leniently, with agents 
shown to be safe and effective [15]. A holistic approach to T2DM management in HF should also include 
blood pressure, body weight, and lipid control, while avoiding hypoglycaemia, which is associated with 
a greater risk of death [16] and may be a cause of increased mortality in diabetic patients with HF on 
insulin therapy [17]. However, this may be challenging in clinical practice, as older age, frailty and 
multiple comorbidities, including coronary artery disease (CAD), and chronic kidney disease (CKD) [6, 
18], increase the vulnerability to adverse drug effects in many patients with T2DM and HF.  
New glucose-lowering medications (i.e. dipeptidyl peptidase 4 (DPP-4) inhibitors [19], glucagon 
like peptide-1 receptor agonists (GLP-1 RA) [20], and sodium glucose cotransporter type-2 (SGLT-2) 
inhibitors [21]) may have effects beyond glycaemic control pertinent to cardiovascular (CV) risk 
reduction in T2DM. Figure 1 provides a summary of several proposed pleiotropic mechanisms that 
extend the benefits of new glucose lowering medications beyond glycaemic control to include positive 
metabolic, renal, vascular and haemodynamic effects [22]. At present, the exact mechanism(s) 
underlying favourable CV effects of these medications in humans are unclear and are under 
assessment in several mechanistic studies. However, the results from large CV outcome trials (CVOTs) 
have shown a comprehensive CV risk reduction with some of the new glucose-lowering agents, in 
particular with GLP-1 RA and SGLT-2 inhibitors, in patients with T2DM and established CV disease or 
with multiple risk factors. However, clinically relevant issues have been raised about the effectiveness 
and safety of these medications relevant for HF outcomes. Therefore, the purpose of this position paper 
is to summarize clinical trial data on the role and safety of these new evidence-based therapies for the 
treatment of T2DM in patients with HF.  
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HEART FAILURE OUTCOMES IN CARDIOVASCULAR OUTCOME TRIALS WITH NEW 
GLUCOSE-LOWERING MEDICATIONS  
Since 2008 and 2012, Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA), respectively, have required that CVOTs investigating novel glucose-lowering 
medications are designed to evaluate CV safety. To minimize potential confounding by differences in 
glycaemic control between the treatment groups, CVOTs promoted a concept of “glycaemic equipoise” 
(i.e. maintenance of similar glycaemic levels during the trial) between the treatment arms. In the majority 
of CVOTs, primary outcome has been a composite of the three major adverse CV events (3-point 
MACE) comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke. Two trials also 
included hospitalisation for unstable angina (4-point MACE) [23, 24], and one trial had two co-primary 
outcomes (the 3-point MACE and a composite of CV mortality and HF hospitalisation) [25]. Most 
patients had a history of long-standing T2DM and established atherosclerotic CV disease (or 
alternatively were at high CV risk) and, therefore, the evidence derived from these trials is most 
compelling for secondary prevention of CV events. Despite the undisputed relevance of HF in patients 
with T2DM, none of these trials included HF events as a component of the primary outcome. However, 
hospitalisation for HF was a prespecified secondary outcome in all trials, and a co-primary composite 
outcome in one of the trials with SGLT-2 inhibitors [25]. Until recently, the generalisation of trial results 
to individuals with HF was hampered by the relatively modest number of patients with a history of HF 
enrolled, ranging 9-28% (Tables 1, 2 and 3) and limited characterisation of HF in terms of left ventricular 
(LV) ejection fraction (LVEF), aetiology, functional class or biomarker levels, either at baseline, or during 
the follow-up,  with a possible exception, to some extent, of DECLARE-TIMI 58 trial (Dapagliflozin Effect 
on Cardiovascular Events –Thrombolysis in Myocardial Infarction 58) [25]. However, recently completed 
DAPA-HF (Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death 
in Patients With Chronic Heart Failure) has shown a significant reduction in CV mortality and HF events 
with dapagliflozin vs. placebo among patients with HF and reduced ejection fraction (HFrEF), regardless 
of T2DM status, suggesting that these medications could be beneficial in the treatment of HF [26]. 
Furthermore, observational and registry data suggest similar efficacy and safety characteristics of the 
new glucose-lowering drugs in “real-world” setting (compared with CVOTs) [27, 28], but current data is 
still limited. 
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DIPEPTIDYL PEPTIDASE-4 INHIBITORS 
The CVOTs with DPP-4 inhibitors (saxagliptin, alogliptin, sitagliptin, and linagliptin) have 
demonstrated non-inferiority to placebo in respect to primary 3-point MACE, but they have not shown 
superiority. A summary of CVOT results with DPP-4 inhibitors are presented in Figure 2. Despite a 
consistently neutral effect on the primary composite outcome, the rates of HF hospitalisation were 
different among the DPP-4 inhibitors. (Table 1). In the SAVOR-TIMI 53 trial (Saxagliptin Assessment 
of Vascular Outcomes Recorded in patients with diabetes mellitus - Thrombolysis In Myocardial 
Infarction 53) [29], a statistically significant increase of 27% in hospitalisation for HF was observed in 
patients randomised to saxagliptin vs. placebo (3.5% vs 2.8%; hazard ratio (HR), 1.27; 95% confidence 
interval (CI), 1.07-1.53) [30]. The EXAMINE trial (Examination of Cardiovascular Outcomes vs. 
Standard of Care in Patients with Type 2 Diabetes and Acute Coronary Syndrome) demonstrated a 
nonsignificant trend towards increased risk of HF hospitalisation with alogliptin vs. placebo (3.1% vs. 
2.9%; HR, 1.07; 95% CI 0.79-1.46) [31]. In the TECOS (Trial Evaluating Cardiovascular Outcome with 
Sitagliptin), sitagliptin demonstrated no effect on the risk of HF hospitalisation compared to placebo 
(3.1% vs. 3.1%, HR, 1.00; 95% CI 0.84-1.20) [23]. In the most recent trial investigating this class of 
agents, CARMELINA (Effect of Linagliptin vs. Placebo on Major Cardiovascular Events in Adults With 
Type 2 Diabetes and High Cardiovascular and Renal Risk), there was no significant effect of linagliptin 
vs. placebo treatment on the risk of HF hospitalisation (2.8% vs. 3.0%; HR, 0.90; 95% CI, 0.74-1.08) 
[32], as well as other HF outcomes, including CV death or HF hospitalisation (HR, 0.94; 95% CI, 0.82–
1.08), or recurrent HF hospitalisation events (326 versus 359 events, respectively; rate ratio, 0.94; 95% 
CI, 0.75–1.20) [33].   
Whether DPP-4 inhibitors increase the risk of HF in general, or exhibit within-class differences, 
is not completely understood. A post hoc analysis of SAVOR-TIMI 53 has suggested a higher risk with 
saxagliptin in patients with a history of HF, renal dysfunction (estimated glomerular filtration rate eGFR 
<60 ml/min [34]) and higher baseline levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
[30]. However, this was not observed with alogliptin in a post hoc analysis of EXAMINE, in which the 
risk of HF hospitalisation was unaffected by the above-mentioned factors [31]. Notably, the higher 
incidence of HF hospitalization has not resulted in excess all-cause or CV mortality in the group treated 
with either saxagliptin in SAVOR-TIMI 53, or alogliptin in EXAMINE [29, 35]. In a prespecified sub-
analysis of CARMELINA, linagliptin was safe for HF outcomes in patients with or without prior HF, 
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irrespective of LVEF, and across a spectrum of renal impairment [33]. In the smaller VIVIDD study 
(Effects of Vildagliptin on Ventricular Function in Patients with Type 2 Diabetes Mellitus and Heart 
Failure), vildagliptin had no significant effect on LVEF, BNP levels, or HF status in patients with HF and 
reduced ejection fraction (HFrEF) [36]. However, treatment with vildagliptin resulted in an increase in 
LV volumes and more deaths compared with placebo (8.6% vs. 3.2%), albeit with no consistent pattern 
and not reaching statistical significance [36]. The clinical significance of these findings remains to be 
determined.  
Several meta-analyses of these trials have indicated either a higher risk of HF in patients with 
established CV disease [37], or a higher HF risk associated with saxagliptin, but not with other DPP-4 
inhibitors [38]. A recently presented CAROLINA trial (Cardiovascular Outcome Study of Linagliptin 
versus Glimepiride in Patients with Type 2 Diabetes) demonstrated no difference in the 3-point MACE 
outcome and no increase in the risk of HF hospitalisation (3.7% vs 3.1%; HR, 1.21; P = 0.176) between 
linagliptin and an active comparator, glimepiride, but patients treated with glimepiride experienced more 
hypoglycaemia compared with those receiving linagliptin (NCT01243424, [39]).  
GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS 
Six CVOTs have assessed the CV safety profile of the subcutaneous GLP-1 RA class of agents 
(lixisenatide, liraglutide, semaglutide, exenatide, albiglutide and dulaglutide) and one trial has evaluated 
the first orally active form of the GLP-1 RA, oral semaglutide [40], Table 2. Two of these CVOTs, ELIXA 
(Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome) [41] and EXSCEL 
(Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes) [42], found that 
lixisenatide and exenatide, respectively, had a neutral effect on the primary composite outcome. There 
was no effect of lixisenatide (4.2% vs. 4.0%; HR 0.96, 95%CI 0.75-1.23) or exenatide (3.0% vs. 3.1%, 
HR, 0.94; 95% CI, 0.78−1.13) vs. placebo on the risk of HF hospitalisation [41, 42]. Conversely, CVOTs 
with liraglutide, semaglutide and albiglutide have shown a reduction in CV outcomes compared with 
placebo. A summary of CVOT outcomes with GLP-1 RA is shown in Figure 2.  
In LEADER (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes), liraglutide 
treatment led to a decrease of 13% in the risk of primary endpoint MACE, as well as significantly lower 
risks of CV mortality, all-cause mortality and microvascular events compared to placebo [43]. There 
was a nonsignificant 13% reduction in the risk of HF hospitalisation, (4.7% vs. 5.3%; HR, 0.87; 95% CI, 
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0.73 - 1.05) [43]. In SUSTAIN-6 (Semaglutide and Cardiovascular Outcomes in Patients with Type 2 
Diabetes), subcutaneous semaglutide led to a 26% lower risk of the primary endpoint MACE, mainly 
driven by a reduction in the rate of stroke [44]. The relative risk of HF hospitalisation was unaffected by 
semaglutide treatment (3.6% vs. 3.3%; HR, 1.11; 95%, 0.77 - 2.78) [44]. Recently, PIONEER 6 trial 
(Peptide Innovation for Early Diabetes Treatment) explored CV safety of the first oral GLP-1 RA 
compared with placebo. The trial demonstrated no excess in the risk of 3-point MACE (2.9% vs. 3.7%; 
HR, 0.79, 95% CI, 0.57 – 1.11) and no increase in HF hospitalisation (1.3% vs. 1.5%; HR 0.86, 95% 
CI, 0.48 – 1.55) with oral semaglutide compared with placebo [40]. Furthermore, the results of 
PIONEER 7 (Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in 
type 2 diabetes: a multicentre, open-label, randomised, phase 3a trial) suggest that flexible dose-
adjusted oral semaglutide can provide superior glycaemic control and weight loss compared with 
sitagliptin, with safety characteristics similar to subcutaneous GLP-1 RAs [45]. These results open a 
possibility to further explore oral GLP-1 RA as an alternative to the injectable form of these medications. 
Recently, in HARMONY Outcomes (Albiglutide and Cardiovascular Outcomes in Patients with 
Type 2 Diabetes and Cardiovascular Disease) there was a 22% lower risk of the primary composite 
outcome with albiglutide compared with placebo, driven by a significant reduction in the rate of MI [46]. 
Also, a trend was observed towards a lower risk of the composite outcome of CV death or hospital 
admission for HF with albiglutide compared with placebo (4.0% vs. 5.0%; HR, 0.85, 95% CI, 0.70–1.04) 
[46]. In addition, the REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in 
Diabetes) demonstrated a 12% risk reduction for the 3-point MACE with the long-acting dulaglutide vs. 
placebo (12.0% vs. 13.4%; HR, 0.88, 95% CI, 0.79-0.99), primarily due to a significant reduction in the 
risk of non-fatal stroke [47]. Again, there was no difference between the two treatment arms with respect 
to HF events (4.3% vs. 4.6%; HR 0.93, 95% CI 0.77 – 1.12) [47].  
A metanalysis of the four trials with a GLP-1 RA has suggested that these medications can 
reduce the rate of 3-point MACE, albeit to a varying degree for individual drugs [20]. The discrepant 
responses may be related to differences in molecular structure and pharmacokinetic properties (long-
acting vs. short-acting) of different GLP-1 RA, or, perhaps, to a heterogeneity in patient risk profiles, 
and study design of particular CVOTs [48]. Improvement in CV outcomes emerged late (after 12 to 18 
months) in the setting of modest glucose-lowering effects and mainly due to a reduction in vascular 
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events (either stroke or MI) suggesting that non-hemodynamic mechanisms beyond glycaemic control, 
possibly related to anti-atherosclerotic effects, underpin the benefits of GLP-1 RA (Figure 1).  
Thus far, GLP-1 RA have shown a neutral effect on the risk of HF hospitalization, with a 
favourable trend observed with liraglutide, albiglutide and oral semaglutide. An observed increase in 
heart rate (by a mean of ∼3-9 beats/minute) may conceivably be partly accountable for the lack of an 
effect on HF [49, 50]. In the recent LIVE study (Effect of liraglutide, a glucagon-like peptide-1 analogue, 
on left ventricular function in stable chronic heart failure patients with and without diabetes), liraglutide 
had a neutral effect on LVEF in patients with chronic stable HFrEF (with or without T2DM), but led to 
an increase in heart rate and more adverse CV events compared with placebo [51]. A similar signal has 
come from the FIGHT trial (Functional Impact of GLP-1 for Heart Failure Treatment) in which a trend 
towards higher risk of death and rehospitalisation for HF was observed with liraglutide compared with 
placebo in HFrEF patients (with or without T2DM) [52]. In a small randomized trial, no significant effect 
was documented with albiglutide on cardiac function or myocardial glucose utilisation in patients with 
symptomatic HFrEF, but there was a modest increase in peak oxygen consumption, the importance of 
which remains to be determined [53]. The suggested safety signal with some of the GLP-1 RA in 
patients with HFrEF merits further investigation.  
SODIUM GLUCOSE COTRANSPORTER TYPE-2 INHIBITORS 
Sodium-glucose cotransporter type-2 (SGLT-2) inhibitors (empagliflozin, canagliflozin, 
dapagliflozin, ertugliflozin) have a unique glucose-lowering effect via inhibiting glucose reabsorption in 
the proximal renal tubule [54]. Due to the favourable outcomes in recent trials, SGLT2 inhibitors are 
assumed to have cardioprotective properties, via several mechanisms, as reviewed [22, 55-57]. 
Beneficial effects of SGLT-2 inhibition on CV outcomes have been shown in the recent landmark 
CVOTs with empagliflozin, canagliflozin and dapagliflozin (Table 3), while ertugliflozin is being 
assessed in an ongoing VERTIS trial (NCT01986881). Notably, SGLT-2 inhibitors are the first class of 
glucose lowering medications that have demonstrated a positive effect on risk reduction for HF 
hospitalization (Figure 2). In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome 
Event Trial in Type 2 Diabetes Mellitus Patients Removing Excess Glucose), empagliflozin treatment in 
patients with T2DM and established CV disease has resulted in a significant 14% relative risk reduction 
for the primary composite outcome, driven by a 38% risk reduction in CV mortality (3.7% vs. 5.9%; HR, 
0.62; 95% CI, 0.49–0.77) [58]. The trial also reported a 35% risk reduction of hospitalisation for HF 
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(2.7% vs. 4.1%, HR, 0.65; 95% CI, 0.5-0.85) and a 32% lower all-cause mortality with empagliflozin 
compared with placebo (5.7% vs. 8.3%; HR, 0.68; 95%, 0.57-0.82) [58]. In a sub-analysis of HF 
outcomes in this trial, empagliflozin reduced the composite risk of HF hospitalisation or CV death (5.7% 
vs. 8.5%; HR, 0.66; 95% CI; 0.55-0.79), as well as its individual components compared to placebo [59]. 
In addition, empagliflozin also reduced HF-related hospitalisation and mortality (2.8% vs. 4.5%; HR; 
0.61; 95% CI, 0.47 – 0.79) [59] and reduced the need for introduction of loop diuretics, which is in 
concert with the observed lower incidence of HF hospitalisation [59, 60]. The beneficial effect of 
empagliflozin on HF hospitalisation was consistent across pre-defined subgroups, including patients 
with and without a history of HF (HRs, 0.75, 95% CI 0.48 - 1.19 and 0.59; 95% CI, 0.43 - 0.82, 
respectively) [59]. The favourable effects on HF events occurred within the first 6 months after treatment 
initiation with an even earlier divergence of the Kaplan-Meier curves, suggesting improvement in 
haemodynamic status and reduced congestion as putative mechanisms (Figure 1). Of note, compared 
with placebo, empagliflozin had no effect on the risk of MI, but there was a numerical increase in the 
risk of stroke (HR, 1.18; 95% CI, 0.89-1.56) [58]. A subsequent sub-analysis showed that this difference 
could be explained by events occurring >90 days after the last dose of the drug, whereas there was no 
difference in events occurring on-treatment or within 90 days after the last dose (HR, 1.08; 95% CI, 
0.81-1.45; P=0.60) [61]. Subsequent CVOTs with other SGLT-2 inhibitors have not shown an increase 
in risk of stroke. 
The CANVAS Program (Canagliflozin Cardiovascular Assessment Study), comprised the 
CANVAS and CANVAS-R trials enrolling T2DM patients with established atherosclerotic CV disease 
(66%), or at high CV risk (34%) [62]. Treatment with canagliflozin resulted in a significant 14% relative 
risk reduction in the primary composite outcome compared with placebo, with the individual components 
demonstrating a statistically non-significant trend towards benefit. This study also showed a substantial 
33% reduction in the risk of HF hospitalisation (5.5% vs. 8.7%; HR, 0.67; 95% CI, 0.52-0.87), although 
this finding was not considered statistically significant based on the prespecified sequence of 
hypothesis testing [62]. An ancillary analysis of CANVAS trial with a retrospective review of medical 
records to obtain data on LVEF at the time of HF hospitalisation demonstrated that the prevailing 
phenotype of HF was HFrEF, defined as admission LVEF <50% (122 cases of 276 HF events), followed 
by HFpEF, defined as LVEF ≥50% (101 cases of 276 HF events), while the rest had HF event with 
unknown LVEF [63]. Patients with HFpEF were more likely to be female, hypertensive and to have high 
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body mass index or microvascular disease in comparison with patients with HFrEF. Importantly, 
canagliflozin reduced the risk of all HF events, with no distinct difference in effects on HFrEF versus 
HFpEF events [63]. 
Further support of the therapeutic benefit with canagliflozin comes from CREDENCE trial 
(Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation), 
showing a 34% relative risk reduction in cardiorenal outcomes compared with placebo in patients with 
T2DM and kidney dysfunction (albuminuria and eGFR 30 to <90 mL/min/1.73 m2) already on optimal 
doses of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers [64]. Importantly, 
this trial has confirmed a robust attenuation in the composite risk of CV death or HF hospitalisation (HR 
0.69; 95% CI, 0.57-0.83), including a significant risk reduction for HF hospitalisation. On that basis, 
SGLT-2 inhibition may be a novel approach to improve cardiorenal protection and reduce the risk of HF 
hospitalisation among high-risk patients with T2DM and mild-to-moderate CKD. 
Recently DECLARE TIMI-58 trial assessed the effects of dapagliflozin vs. placebo on CV 
outcomes in the predominantly (59%) primary prevention population of T2DM patients. Despite a 
neutral effect on the 3-point MACE outcome, dapagliflozin was superior compared with placebo in 
reducing a composite of CV death or HF hospitalization (4.7% vs. 5.8%, HR, 0.83; 95% CI, 0.73 – 0.95) 
[65]. This effect was due to a significant 27% risk reduction for HF hospitalisation (HR 0.73, 95% CI, 
0.61 – 0.88), whereas the risk of CV death was unaffected [65]. Further insights into the effects of 
dapagliflozin according to baseline HF status (with or without a history of HF) and LVEF came from a 
sub-analysis of DECLARE-TIMI 58 trial, demonstrating consistent reduction in the risk of HF 
hospitalisation in all patients, regardless of baseline HF status or LVEF [66]. However, the largest risk 
reduction in HF hospitalisation was observed in patients with HFrEF (3.9% in patients with baseline 
LVEF <45%), in whom dapagliflozin also attenuated all-cause and CV mortality [66]. By contrast, in 
non-HFrEF patients (either without known HF or without known reduced LVEF), HF risk reduction was 
lower compared with HFrEF patients and there was no effect on mortality. Yet another sub-analysis of 
the same trial has demonstrated a reduction in hospitalisation irrespective of baseline CV risk profile 
(established CV disease or multiple risk factors), albeit individuals with prior MI derived the greatest 
benefit, including a reduction in the risk of 3-point MACE with dapagliflozin [67]. 
Several haemodynamic and metabolic mechanisms (not mutually exclusive) have been 
proposed to explain the salutary CV effects of SGLT-2 inhibitors (Figure 1) [22], but they await 
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confirmation from clinical trials. In a recent exploratory analysis of EMPA-REG OUTCOME, changes in 
markers of plasma volume (haematocrit and haemoglobin) had the largest impact on relative risk 
reduction of CV death (51.8% and 48.9%, respectively) [68]. These changes were likely haemodynamic 
in origin, reflecting a sustained effect on plasma volume contraction owing to increased diuresis and 
natriuresis with SGLT-2 inhibitors. SGLT-2 inhibitors exert renal protection [58, 62, 65], which could 
also contribute to CV protection. Furthermore, in a mechanistic experimental study, empagliflozin has 
been associated with an improvement in myocardial diastolic stiffness in isolated human 
cardiomyocytes, most likely due to enhanced phosphorylation of myofilament regulatory proteins [69]. 
A subanalysis of a small number of patients from EMPA-REG OUTCOME has shown early and 
significant reduction in LV mass index and improvement in diastolic function without changes in LV 
systolic function or volumes with empagliflozin compared with placebo [70]. Most recently, EMPA-
HEART Cardiolink-6 study has shown a reduction in LV mass index on cardiac magnetic resonance 
following 6 months of empagliflozin treatment (compared with placebo) among diabetic patients with 
stable CAD, normal LVEF and without a history of HF [71]. Although intriguing, these concepts require 
further confirmation from larger studies [56]. The results of DAPA-HF suggest that SGLT-2 inhibitors 
may indeed benefit the treatment of HF, as discussed below. 
A SUGGESTED APPROACH TO GLUCOSE-LOWERING THERAPY IN PATIENTS WITH 
TYPE 2 DIABETES AND HEART FAILURE 
Recent CVOTs provide a perspective on the role and safety profile of new glucose-lowering 
medications for the treatment of T2DM in patients with HF.  
There is currently insufficient evidence on the safety profile of DPP-4 inhibitors in patients with 
established HF. Based on the available data, saxagliptin, and, possibly, vildagliptin should not be used 
in those patients, while caution is recommended with alogliptin. There is no evidence of adverse HF 
outcomes with linagliptin, or sitagliptin.  
In the general population of T2DM patients, DPP-4 inhibitors are well tolerated, weight-neutral 
and associated with a low risk of hypoglycaemia (Figure 3). The recommended doses, dose 
modifications and important precautions relevant for DPP-4 inhibitors use are presented in Figure 3.  
GLP-1 RA demonstrated a neutral effect on the risk of HF, and a trend towards a lower risk 
was observed with liraglutide, albiglutide and oral semaglutide. However, a signal of harm detected in 
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smaller trials of GLP-1 RA in patients with HFrEF warrants caution. Therefore, this concerning safety 
issue needs further investigation prior to defining the role of GLP-1 RA for T2DM treatment in patients 
with established HF.  
The risk of hypoglycaemia is not increased with GLP-1 RA monotherapy but may be aggravated 
in combined treatment with other glucose-lowering drugs, in particular insulin or insulin secretagogues. 
The therapy with GLP-1 RA increases postprandial satiety that may have favourable effect on weight 
loss. The most frequent side-effects of subcutaneous GLP-1 RA include (transient) gastrointestinal 
intolerance, and increased frequency of gall bladder disease  [72]. Gastrointestinal intolerance is also 
the most frequent side-effect of oral semaglutide [40]. There may be an increased risk of acute 
pancreatitis, whereas a higher risk of C-cell hyperplasia/medullary thyroid carcinoma has not been 
confirmed in human studies [72]. The recommended doses, dose modifications, and precautions 
relevant for GLP-1 RA use in general population of patients with T2DM are presented in Figure 3. 
The three CVOTs with SGLT-2 inhibitors have consistently demonstrated that treatment with 
these agents is associated with lower risk of HF hospitalisation in patients with T2DM and established 
atherosclerotic CV disease or with multiple risk factors, with the strongest effects in individuals with 
established CV disease. These results were corroborated by a recent meta-analysis of these CVOTs, 
demonstrating a significant 23% risk reduction for CV death or HF hospitalisation (HR, 0.77; 95% CI 
0.71–0.84), as well as a reduction in HF hospitalisation by 31% (HR, 0.69; 95% 0.61–0.79) with SGLT-
2 inhibitors [73]. Importantly, these findings were consistent regardless of CV disease burden, or a prior 
history of HF, suggesting that SGLT-2 inhibitors may have a beneficial effect on HF prevention in a 
broad spectrum of T2DM patients [73]. 
This beneficial effect has already been acknowledged for empagliflozin in the 2016 ESC 
Guidelines for the diagnosis and treatment of HF [15] and in the Guidelines for cardiovascular 
prevention [74], which have recommended its use in patients with T2DM to delay the onset of HF. In 
line with emerging clinical trial data, the 2019 expert consensus report from the ESC Heart Failure 
Association has extended this recommendation to all three SGLT-2 inhibitors [75]. Likewise, the 2018 
ADA/EASD Consensus statement has positioned SGLT-2 inhibitors as the preferred treatment of T2DM 
in patients with known HF or at risk of HF [76]. Accordingly, SGLT-2 inhibitors have been recommended 
as an add-on therapy in patients who have not achieved adequate glucose control with metformin (or 
in whom metformin is contraindicated/not tolerated) [76]. In patients with HF receiving dual or multiple 
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glucose-lowering medications, not including SGLT-2 inhibitors, a switch to an SGLT-2 inhibitor has been 
recommended [76]. A similar recommendation has been issued from the American College of 
Cardiology [77], however in the absence of prospective data in patients with prevalent HF.  
Clinical trials specifically investigating a potential benefit of this class of drugs in patients with 
prevalent HF, independent of the presence of T2DM, are currently ongoing (Table 4). The first 
completed among those trials, DAPA-HF reported a significant risk reduction in the primary endpoint 
comprising CV mortality/HF hospitalisation/urgent HF visit (HR, 0.74; 95% CI, 0.65 – 0.85) in patients 
with HFrEF (LVEF ≤40% and elevated natriuretic peptides) [26]. Primary composite outcome was 
consistently reduced in patients with T2DM (HR 0.75; 95% CI, 0.63 – 0.90) and in those without T2DM 
(HR 0.73; 95% CI, 0.60 – 0.88). Both components of the primary outcome (CV mortality and HF events) 
were significantly reduced with dapagliflozin treatment (by 18% and 30%, respectively) and there were 
no interactions with respect to demographic/clinical characteristics or HF treatment [26]. Further 
information is awaited from trials with other SGLT-2 inhibitors, including patients with either HFrEF or 
HFpEF, with or without T2DM (Table 4). 
In addition, a clinical trial with sotagliflozin, a unique, dual SGLT-2 and 1 inhibitor is underway 
to investigate CV mortality and HF hospitalisation in patients recently hospitalised for worsening HF 
(NCT03521934). Inhibition of both SGLT-2- and 1 may increase glycosuria beyond the effect observed 
with SGLT-2 inhibitors and to reduce intestinal glucose absorption. However, unlike SGLT-2, SGLT-1 
is also expressed in various other organs, including the heart, where it may have an effect on glucose 
uptake. There is currently a paucity of data to indicate whether these effects could have incremental 
therapeutic value in patients with T2DM [78]. 
SGLT-2 inhibitors are associated with a low risk of hypoglycaemia and can be safely and 
effectively combined with other glucose-lowering drugs in order to achieve optimal glucose control [79]. 
However, adverse effects need to be considered. The most frequently observed adverse events are 
genital mycotic infections, usually mild and non-recurring after treatment [58, 62, 65]. Rarely, 
“euglycaemic” ketoacidosis may occur (characterised by lower than typical blood glucose levels), 
possibly caused by increased glucagon release and decreased renal ketone body excretion in the face 
of enhanced glycosuria in insulin deficient patients (i.e. patients receiving insulin therapy) [80]. Although 
ketoacidosis has not been more frequently observed in EMPA-REG OUTCOME or CANVAS trials, it 
occurred more frequently with dapagliflozin in DECLARE TIMI 58 (HR, 2.18; 95% CI, 1.10 – 4.30) [65]. 
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Hospitalisation for an acute illness or surgery may exacerbate the risk of ketoacidosis, and it may be 
prudent to temporarily discontinue SGLT-2 inhibitors under those circumstances [81, 82]. Reinitiating 
SGLT-2 inhibitors following the episode of ketoacidosis is not recommended because of an increased 
risk of recurrence [81, 82]. In addition, safety analyses of CANVAS Program have suggested a greater 
risk of bone fractures and lower limb amputations with canagliflozin. The most prominent increase in 
the absolute risk was observed among patients with previous amputations or peripheral arterial disease, 
possibly explained by volume depletion and greater vulnerability to ischaemic complications [62]. By 
contrast, no significant increase in the risk of lower-limb amputations, or fractures was observed with 
canagliflozin in CREDENCE. Of note, in DAPA-HF, among the high-risk HFrEF patients with or without 
T2DM, no significant excess in serious adverse events was noted with dapagliflozin vs. placebo 
(including fractures, amputations or ketoacidosis in patients with T2DM) [26].  
The three SGLT-2 inhibitors (empagliflozin, canagliflozin or dapagliflozin) can be considered 
patients with eGFR ≥30 mL/min/1.73 m2 [83]. They are not recommended/should be discontinued in 
patients with severe CKD; i.e. eGFR <30 mL/min/1.73 m2 (Figure 5). Considering a predilection for 
worsening renal function in patients with HF, an emphasis should be given on regular eGFR monitoring 
in patients treated with SGLT-2 inhibitors.   
Dosing and precautions pertinent to SGLT-2 inhibitor therapy in the general population of 
patients with T2DM are presented in Figure 5. 
 
SAFETY ASPECTS OF COMBINING NEW AND TRADITIONAL GLUCOSE-LOWERING 
MEDICATIONS 
Although metformin has not been evaluated in a randomized trial in HF population, a substantial 
body of observational data indicates that it is safe and associated with a reduction in all-cause mortality 
and rehospitalisation for HF, compared with sulphonylureas or insulin [84-88]. These benefits extend to 
patients with advanced HFrEF [84], as well as to patients with moderate renal or hepatic dysfunction 
[88, 89], in whom aggravated risk of lactic acidosis with metformin has not been confirmed [88]. Severe 
CKD (eGFR <30 mL/min/1.73 m2) remains a contraindication for metformin use, and dose adjustment 
is advised in patients with eGFR <45 mL/min/1.73 m2. A favourable impact on CV outcomes, coupled 
with a low risk of hypoglycaemia, a neutral effect on body weight, and low cost, have led to the current 
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recommendation that metformin should be considered in T2DM in HF patients with stable eGFR >30 
mL/min/1.73 m2 [83]. It is also the preferred choice in the combined treatment with SGLT-2 inhibitors, 
intending to achieve both optimal glycaemic control and risk reduction of HF hospitalization [72].  
Earlier clinical trials with thiazolidinediones (pioglitazone, rosiglitazone) have consistently 
demonstrated an increased risk of HF compared with placebo [90-92]. Furthermore, a meta-analysis 
including 20 191 patients from 7 trials reported a significantly higher risk of HF with thiazolidinediones 
[93].  
The possible underlying mechanisms include increased renal fluid reabsorption and increased 
vascular permeability leading to oedema formation and weight gain [94]. Hence, thiazolidinediones are 
contraindicated in patients with HF, or at high risk of developing HF, and there is insufficient data to 
indicate that this risk is mitigated by the combined treatment with novel glucose lowering agents.  
Similar to metformin, sulfonylureas (gliclazide, glimepiride, glipizide, and glibenclamide [95]) 
and glinides (repaglinide and nateglinide) have not been prospectively evaluated for CV safety. Data 
on HF outcomes are sparse and difficult to generalize to all sulphonylureas/glinides. A recent propensity 
score-matched analysis of 130,000 patients (6% with a history of HF), has suggested a greater risk of 
HF hospitalisation or CV death with sulfonylureas compared with metformin [96]. A recent cohort study 
of almost 500,000 patients reported a higher all-cause mortality in patients receiving sulphonylurea 
monotherapy or a combination therapy with insulin, whereas the risk was not increased when 
sulphonylureas were combined with metformin, thiazolidinediones or DPP-4 inhibitors [97]. There is 
limited data to indicate a heterogeneity in CV benefits of the new glucose-lowering drugs in combination 
with sulphonylureas or glinides, but a dose adjustment of the letter drugs may be needed to avoid the 
risk of hypoglycaemia. As the risk of hypoglycaemia with sulphonylureas tends to escalate with 
declining renal function, these medications are not recommended in patients with severe CKD (eGFR 
<30 mL/min/1.73 m2) [72, 98, 99]. 
Insulin therapy is widely used in patients with T2DM, but only a few studies have investigated 
its association with HF. Data from the CHARM (Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity) have suggested a higher risk of HF and worse outcomes in patients receiving 
insulin compared to those treated with oral glucose-lowering agents [100]. Conversely, in the UKPDS 
(UK Prospective Diabetes Study) there was no difference in the incidence of HF between patients 
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receiving insulin and those receiving sulphonylurea [101]. In the ORIGIN trial (Outcome Reduction With 
Initial Glargine Intervention), among 12,537 patients with different levels of dysglycaemia (impaired 
glucose tolerance, impaired fasting glucose, or T2DM) and CV risk factors, randomized to basal insulin 
glargine or placebo, there were no differences in CV outcomes, including HF hospitalisation [102]. In 
the recent CVOTs with SGLT-2 inhibitors, about 40-50% of patients were already treated with insulin 
and subgroup analyses of all trials have demonstrated no interaction with CV outcomes in patients with 
or without insulin. However, insulin therapy may increase the risk of hypoglycaemia, and dose-
adjustment is necessary in individuals treated concomitantly with new glucose-lowering agents. In 
addition, insulin has an intrinsic anti-natriuretic effect [103], unaffected by insulin resistance in other 
tissues [104]. Although fluid retention is usually mild, it may contribute to weight gain, and lead to 
worsening HF.  Of note, data from an observational cohort including patients with HFrEF and advanced 
HF, suggest that insulin therapy has been associated with significantly higher one-year mortality [105]. 
Although available data suggests mostly neutral effect of insulin on the risk of HF, further 
research is required to address risks and benefits of different insulin regimens in patients with HF.  
Although all new glucose-lowering agents carry a low risk of hypoglycaemia when used as a 
monotherapy or in combination with metformin, this risk may be potentiated when combined with insulin 
or insulin secretagogues (i.e. sulphonylurea, glinides). Current recommendations from the ADA and 
EASD stipulate dose-adjustment or even discontinuation of some of antihyperglycemic agents to 
prevent hypoglycaemia when initiating a new glucose-lowering medication in patients already receiving 
insulin and/or insulin secretagogues [76]. In addition, decompensated HF, worsening renal function, 
infection and other critical conditions, may exacerbate the risk of hypoglycaemia. Hence, a 
multidisciplinary team management (cardiologists, diabetologists, and HF nurses) should be considered 
in patients receiving complex glucose-lowering regiments (two or more drugs). Even in T2DM patients 
principally managed by the cardiologists, periodic consultation with a diabetologist would be important. 
Future long-term follow-up studies with concomitant assessment of adherence should consider the 
potential risks of polypharmacy, in terms of adverse reactions, and drug to drug interactions, especially 
among vulnerable patients with HF and T2DM, such as the elderly, frail and associated multi-comorbid 
conditions. 
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CONCLUSIONS 
Over the last decade, management of T2DM has evolved from optimising glycaemic control 
with the primary aim of preventing the development or progression of microvascular complications 
(retinopathy, nephropathy and neuropathy), to using new glucose-lowering medications for improving 
CV outcomes, including prevention of HF hospitalisation. Recent CVOTs have shown a heterogeneity 
with respect to risk of HF among the classes of new glucose-lowering drugs. Specifically, important 
safety concerns have been raised regarding the risk of HF hospitalization with some of these classes 
of agents. Accordingly, a DPP-4 inhibitor, saxagliptin should not be prescribed to patients with HF, 
whilst caution is advised with alogliptin and vildagliptin. Although sitagliptin and linagliptin do not 
increase HF risk, they have no clear effect on CV outcomes, so their use needs to be compared with 
benefits demonstrated with other classes, including several of the GLP-1 RA and SGLT-2 inhibitors. 
Based on published CVOTs, GLP-1 RA have demonstrated a neutral effect on HF risk in the general 
population of T2DM patients with established CV disease or with multiple risk factors. In addition, their 
beneficial effects on weight and prevention of atherosclerotic events (MI and stroke) deserve 
consideration in T2DM patients deemed to have high CV risk. However, a signal of harm with liraglutide 
suggested by two small randomised trials of patients with reduced LVEF, indicates that the role GLP-1 
RA remains to be defined in individuals with established HF. The three SGLT-2 inhibitors (empagliflozin, 
canagliflozin and dapagliflozin) have consistently demonstrated a substantial reduction in the risk of HF 
hospitalisation across the spectrum of CV risk and regardless of a history of HF. On that basis, SGLT-
2 inhibitors could be recommended to prevent HF hospitalisation in patients with T2DM and high CV 
risk. Importantly, this class of medications has a favourable safety profile, with low risk of hypoglycaemia 
and beneficial effect on weight control, while serious adverse events (e.g. ketoacidosis, bone fracture 
or limb amputations) occur infrequently and could be avoided by appropriate patient selection and 
monitoring. Despite encouraging results with dapagliflozin, it remains to be determined in ongoing 
clinical trials whether SGLT-2 inhibitors could be used for the treatment of HF, with or without reduced 
LVEF, and whether their beneficial CV effects could be extended to HF patients without T2DM. 
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Figure legend 
Figure 1. Proposed mechanisms of pleiotropic effects of new glucose-lowering 
medications. 
DPP-4 i – Dipeptidyl peptidase-4 inhibitor; FFA – free fatty acid; GI – gastrointestinal motility; GLP-1 RA – glucagon-
like protein-1 receptor agonist; SGLT-2 i – sodium-glucose cotransporter inhibitor 
Figure 2. Summary of clinical trial results with new glucose-lowering medications in 
patients with type 2 diabetes mellitus 
*In the co-primary efficacy analyses, dapagliflozin did not reduce the risk of 3-point MACE (hazard ratio, 
0.93; 95% confidence interval, 0.84 to 1.03; P=0.17) but did result in a lower risk of cardiovascular death or 
hospitalization for heart failure (hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005). 
Figure 3. DPP-4 inhibitors: dosing, dose-adjustment and precautions 
Figure 4. GLP-1 RA: dosing, dose-adjustment and precautions 
Figure 5. SGLT-2 inhibitors: dosing, dose adjustment and precautions  
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Table 1. Risk of HF hospitalisation in CV outcome trials with DPP-4 inhibitors 
Medication Trial Patients, n Patient characteristics 
HbA1c 
(mean) 
History of HF, 
n (%) 
Follow-up (mean 
or median) 
HF hospitalisation 
(HR, 95% CI)* 
P-value 
Saxagliptin 
SAVOR-TIMI 
53 [29, 30] 
16,492 
Established CVD; 
multiple CV risk factors 
8.0% 2,105 (13%) 2.1 years 1.27 (1.07-1.51) 0.007 
Alogliptin 
EXAMINE 
[31] 
5,380 
Recent acute coronary 
syndrome 
8.0% 1,533 (28%) 1.5 years 1.07 (0.79 - 1.46) 0.66 
Sitagliptin TECOS [23] 14,671 Established CVD 7.2% 2,643 (18%) 3 years 1.00 (0.83 - 1.20) 0.98 
Linagliptin 
CARMELINA 
[32] 
6,991 High CV and renal risk ∼7.9% 1,876 (27%) 2.2 years 0.90 (0.74 -1.08) 0.26 
HF – Heart failure; HR – hazard ratio; CI – confidence interval; CVD – cardiovascular disease; CV - cardiovascular 
*treatment vs. placebo 
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Figure 2. Summary of clinical trial results with new glucose-lowering medications   
 
 
 
 
 
Table 2. Risk of HF hospitalisation in CV outcome trials with GLP-1 RA  
Medication Trial Patients, n Patient characteristics 
HbA1c 
(mean) 
History of 
HF, n (%) 
Follow-up (mean 
or median) 
HF hospitalisation 
(HR, 95% CI)* 
P-value 
Lixisenatide ELIXA [41] 6,068 
Recent acute coronary 
syndrome 
∼7.7% 1,358 (22%) 2.1 years 0.96 (0.75 – 1.23) 0.75 
Liraglutide 
LEADER 
[43] 
9,340 
Age ≥50 years and 
established CVD; 
Age ≥60 years and CV 
risk factors 
8.7% 1,667 (18%) 3.8 years 0.87 (0.73 – 1.05) 0.14 
Semaglutide 
(subcutaneous) 
SUSTAIN-6 
[44]. 
3,297 
Age ≥50 years and 
established CVD; 
Age ≥60 years and CV 
risk factors 
8.7% 777 (24%) 2.1 years 1.11 (0.77 – 1.61) 0.57 
Semaglutide 
(oral) 
PIONEER-6 
[40]  
3,183 
Age ≥50 years and 
established CVD; 
Age ≥60 years and CV 
risk factors 
8.2% 388 (12%) 1.3 years 0.86 (0.48 – 1.55) --- 
Exenatide 
EXSCEL 
[42] 
14,752 
Established CVD (73%) 
CV risk factors (37%) 
8.0% 2389 (16%) 3.2 years 0.94 (0.78 – 1.13) --- 
 31 
Albiglutide 
HARMONY 
Outcome 
[46] 
9,463 Established CVD ∼8.7% 1,922 (20%) 1.5 years 0.85 (0.70 – 1.04)** 0.11 
Dulaglutide 
REWIND 
[47] 
9,901 
Established CVD 
(31.5%) 
CV risk factors (68.5%) 
∼7.3% 853 (8.6%) 5.4 years 0.93 (0.77 – 1.12)† 0.46 
HF – Heart failure; HR – hazard ratio; CI – confidence interval; CVD – cardiovascular disease; CV - cardiovascular 
*treatment vs. placebo 
**A composite of CV death or HF hospitalisation 
†HF hospitalisation or urgent HF visit 
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Table 3. Risk of HF hospitalisation in CV outcome trials with SGLT-2 inhibitors 
Medication Trial Patients, n Patient characteristics 
HbA1c 
(mean) 
History of HF 
Follow-up (mean 
or median) 
HF hospitalisation 
(HR, 95% CI)* 
P-value 
Empagliflozin 
EMPA-REG 
OUTCOME 
[58] 
7,020 Established CVD 8.1% 10% 3.1 years 0.65 (0.50-0.85) 0.002 
Canagliflozin 
CANVAS 
Program [62] 
10,142 
Established CVD (66%); 
CV risk factors (34%) 
8.2% 14% 3.2 years 0.67 (0.52–0.87) --- 
Canagliflozin 
CREDENCE 
[64] 
4,401 
Albuminuric chronic 
kidney disease** 
8.3% ∼15% 2.62 years 0.61 (0.47–0.80) <0.001 
Dapagliflozin 
DECLARE 
TIMI-58 [65] 
17,160 
Established CVD (41%) 
CV risk factors (59%) 
8.3% 10% 4.2 years 0.73 (0.61-0.88) --- 
Dapagliflozin 
DAPA-HF 
[26] 
4,744  
Symptomatic HF (NYHA 
II-IV), NT-proBNP ≥ 600 
pg/mL (or ≥400 pg/mL if 
hospitalised for HF within 
the previous 12 months; 
if AF/AFL ≥900 pg/mL). 
A history of 
T2DM: 
42% 
100% 1.5 years 0.70 (0.59 - 0.83) --- 
HF – Heart failure; HR – hazard ratio; CI – confidence interval; CVD – cardiovascular disease; CV – cardiovascular 
*treatment vs. placebo 
**Estimated glomerular filtration rate: 30 to <90 ml/min/1.73 m2 and albuminuria: albumin-to-creatinine ratio >300 to 5000 mg/g 
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Table 4. Selected ongoing randomized clinical trials of SGLT2 inhibitors in patients with heart failure  
Clinical trial Brief description of the trial 
EMPAGLIFLOZIN  
EMPA-RESPONSE-AHF 
(NCT03200860) 
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure 
• Study population: acute decompenzated heart failure 
• Estimated enrolment: n=80. 
• Treatment: empagliflozin vs. Placebo 
• Primary outcome: Change in NTproBNP. Secondary outcome: All Cause Mortality or HF readmission 
EMPEROR-Reduced 
(NCT03057977) 
 
Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction 
• Study population: HFrEF, with or without T2DM. 
• Estimated enrolment: n=2850. 
• Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
• Primary outcome: CV death or HF hospitalization (time frame: up to 38 months). 
EMPEROR-Preserved 
(NCT03057951) 
 
Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction 
• Study population: HFpEF, with or without T2DM. 
• Estimated enrolment: n=6000. 
• Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
• Primary outcome: CV death or HF hospitalization (time frame: up to 38 months). 
Empire HF (NCT03198585) 
 
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction 
• Study population: HFrEF, with or without T2DM. 
• Estimated enrolment: n=189. 
• Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: 90 days) as a measure of treatment impact on HF. 
EMPERIAL-Reduced 
(NCT03448419) 
 
Empagliflozin in Patients With HFrEF: aiming to assess how far patients can walk in 6 minutes and their symptoms  
• Study population: HFrEF (LVEF <40%), with or without T2DM. 
• Estimated enrolment: n=300. 
• Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
• Primary outcome: change from baseline to week 12 in exercise capacity as measured by the distance walked in 6 minutes in standardised 
conditions 
EMPERIAL-Preserved 
(NCT03448406 
Empagliflozin in Patients With HFpEF: aiming to assess how far patients can walk in 6 minutes and their symptoms  
• Study population: HFrEF (LVEF ≥40%), with or without T2DM. 
• Estimated enrolment: n=300. 
• Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
• Primary outcome: change from baseline to week 12 in exercise capacity as measured by the distance walked in 6 minutes in standardised 
conditions 
CANAGLIFLOZIN  
Canagliflozin (NCT02920918) Treatment of Diabetes in Patients With Systolic Heart Failure 
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• Study population: HFrEF with T2DM. 
• Estimated enrolment: n=88. 
• Treatment: canagliflozin vs. sitagliptin. 
• Primary outcome: change in aerobic exercise capacity and ventilator efficiency (time frame: baseline and 12 weeks). 
DAPAGLIFLOZIN  
DEFINE-HF 
(NCT02653482) 
Dapagliflozin Effect on Symptoms and Biomarkers in Diabetic Patients With Heart Failure 
• Study population: HFrEF with T2DM. 
• Estimated enrolment: n=250. 
• Treatment: dapagliflozin vs. placebo. 
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: 12 weeks) as a measure 
• of treatment impact on HF 
DELIVER 
(NCT03619213) 
Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure 
• Study population: HFpEF 
• Estimated enrolment: n=4,700 
• Treatment: dapagliflozin vs. placebo 
• Primary outcome: Composite of CV death, hospitalisation for HF or urgent HF visit. Secondary outcome: hospitalisations for HF and CV death, 
worsened NYHA class 
DETERMINE–reduced 
(NCT03877237) 
Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction 
• Study population: HFrEF, EF ≤ 40%; NYHA Class II-IV 
• Estimated enrolment: n= 300  
• Treatment: dapagliflozin vs. placebo. 
• Primary outcome: change from baseline in 6-minute walking distance at week 16 
DETERMINE–preserved  
(NCT03877224) 
Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction 
• Study population: HFpEF, EF > 40%; NYHA Class II-IV 
• Estimated enrolment: n= 400 
• Treatment: dapagliflozin vs. placebo: change from baseline in 6-minute walking distance at week 16 
PRESERVED-HF 
(NCT03030235) 
Dapagliflozin Effect on Symptoms and Biomarkers in patients HFpEF 
• Study population: HFpEF with T2DM or pre-diabetes. 
• Estimated enrolment: n=320. 
• Treatment: dapagliflozin vs. placebo. 
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: baseline to week 6 and 
• 12) as a measure of treatment impact on HF. 
SOLOIST-WHF Trial 
(NCT03521934) 
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure 
• Study population:  a) T2DM, HF and LVEF <50% after admission for worsening HF; b) T2DM, HF, regardless of LVEF after admission for 
worsening HF 
• Estimated enrolment: n=4,000. 
• Treatment: sotagliflozin vs. placebo. 
• Primary outcome: time to first occurrence of either CV death or hospitalisation for HF in patients with LVEF <50%, as well as in the total patient 
population (regardless of LVEF) 
 
